Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis — Stella

Home/Osteoporosis/

View on ClinicalTrials.gov

Recruiting

Back to Osteoporosis trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Taiwan

National Taiwan University Hospital Yunlin Branch, Douliu, Taiwan

Key details

Phase

Post-approval study

Sponsor

National Taiwan University Hospital

Enrollment target

~90 participants

Started

December 2025

Primary completion

July 2026

Age range

50 Years – 80 Years

Sex

Female only

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.